ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

November 07, 2007 09:27 ET

ART Advanced Research Technologies to Present During the Small Animal Imaging Workshop at Stanford University

Hands-on demonstrations will show applications where the Optix imaging system excels in comparison to other modalities

MONTREAL, CANADA--(Marketwire - Nov. 7, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be presenting the applications of time-domain imaging technologies at the Small Animal Imaging Workshop at Stanford University, being held at the Clark Center in Stanford, California, from November 7th to 10th, 2007. Participants at this workshop will learn about the latest preclinical molecular imaging techniques used by researchers to study disease non-invasively and accelerate the discovery, development, and monitoring of novel treatments.

"ART's active participation in workshops, congresses, and scientific meetings are a corner stone of its commercialization strategy," said Mr. Dino DiCamillo, Vice President, Global Sales and Marketing, Preclinical Imaging. "ART is going to continue to develop a brand awareness that is synonymous with technical superiority and customer support," he added.

A talk entitled "Take the measure of life: Time Domain Fluorescence Imaging from ART Advanced Research Technologies" to be given by Mr. Bruno Guerrero, Product Specialist at ART, will take place at 10:20 a.m. local time on November 7th and will describe the applications of time-domain in vivo fluorescence imaging using the Optix® multi-wavelength system. These applications are being used in key therapeutic areas such as oncology, cardiovascular, diseases of the central nervous system, diabetes, among others.

Also, participants will be viewing a number of small animal imaging system demonstrations. Researchers will be conducting experiments on the Optix system installed at Stanford's Clark Center Small Animal Imaging Facility to demonstrate the latest developments in optical/CT fusion and 3D reconstruction capabilities.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART in North America and Europe and is used by industry and academic leaders worldwide. The SoftScan® optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contact Information